Application for the Sci-Tech Innovation Board has been accepted
Application for the proposed initial public issue of A Shares and listing on the Sci-Tech Innovation Board has been accepted by the Shanghai Stock Exchange on May 13, 2019.
Source: FD Zhangjiang
Original: Click here
HK Stock Shanghai Fudan-Zhangjiang Back to SSE Star Market
► Fudan-Zhangjiang Biotech goes public on the Star Market today.
► This follows a trend that is seeing many Hong Kong-listed Chinese pharmaceutical companies go back to list among China's A-shares, with Shanghai's Star Market a coveted destination.
Fudan-Zhangjiang, the Hong Kong-listed biopharmaceutical company, began trading on the Shanghai Star Market at a public offering of CNY 8.95 per share, for 120 million shares. The opening price soared to CNY 35, close to fourfold the IPO price. According to the prospectus, it plans to raise a fund of CNY 650 million. It has invested CNY 230 million in the US registration project for Hemporfin, CNY 240 million in a sustainable project for innovative biopharmaceutical medicine and CNY 180 million in acquiring minority shares of Taizhou Fudan-Zhangjiang.
This IPO is sponsored and underwritten by Haitong Securities, with participation from the other lead underwriter, China International Capital Corporation (CICC). At its IPO, the company’s price-to-earnings ratio (PE) reached 46.93. This Shanghai-based biotech giant gained revenue of CNY 227 million in 2019, over 102.7% higher than its 2018 revenues, with a revenue CAGR of 57.59% from 2017 to 2019.
Fudan-Zhangjiang mainly provides services in biopharmaceutical innovative research and development, manufacturing and marketing. Its photodynamic technology has reached a world-class level and primarily levers this cutting-edge tech in skin venereal disease treatment and oncology therapies, backed by its advanced nanotechnology and genetic engineering.
Fudan-Zhangjiang is not alone. More dual-listed pharmaceutical companies are eyeing the golden opportunities in the Shanghai Star Market. The first ‘NEEQ + H’ stock Junshi Biosciences (1877:HKEX) boarded on the Star Market this May following an estimated valuation of over HKD 20.1 billion publicized last November. Its key product, ‘Tripleitumab,’ as the first-ever domestic PD-1 monoclonal antibody, brought a considerable boost in sales in 2019. All this can be attributed to the R&D investment of CNY 1.9 billion during the last four years.
The Star Market actively welcomes a variety of high-value biotechnology companies, in particular those with sustainable and robust capabilities in research and development – with key attributes being “overvaluation of over CNY 4 billion”, having an “extensive market size,” and “at least one core product moving into clinical Phase II.”
Zelgen (688266:SH), the first A-share list innovation-driven pharmaceutical, focuses on oncology, hemorrhage, blood disease and hepatobiliary diseases. It landed on the Star Market at an IPO issuance price of CNY 33.76, with a closed stock price of 120.94%, higher than the issuance price at a valuation of CNY 17.9 billion.
Bio-Thera Solutions (688177:SH) is Guangzhou-based biotechnology firm dedicated to studying innovative drugs and biosimilar medicines. It mentions the most significant operational risk as considerable losses in its prospectus.
The continued COVID-19 pandemic is raising the wind of investment into research and development. It is the right moment for biopharmaceutical companies listed on the Hong Kong Stock Exchange to look out for more listing opportunities. The Chinese A-market, widely known for overvaluation in dual-listed companies, provides a promising solution.
FD Zhangjiang Applies for Subscription Today, Up to 19,000 Shares in a Single Account.
FD Zhangjiang Will Make Subscription Tomorrow
FD Zhangjiang saw its stock price fell more than 9%.
Fudan Zhangjiang Sci-Tech innovation board IPO registration took effect
In the first quarter of 2020, the revenue of FD Zhangjiang is CNY 34.72 million, and the annual revenue is expected to be CNY 780 million to CNY 900 million.
After the issuance of A-share, FD Zhangjiang opened high on May 15.
FD Zhangjiang (01349.HK) expects first-quarter income of CNY 18.7 million to 36.5 million (-78% yoy)
FD Zhangjiang (01349.HK) plans to adopt accounting standards for Chinese enterprises
There are doubts about figures and fund-raising projects of FD Zhangjiang
EqualOcean is an international information service provider and investment research firm that aims to become a global platform for industrial innovation.
We strive to make technology inclusive, accessible and transparent.
Join over 70,000 of your peers
9 Xiaguangli, 10F Block A CEC Development Mansion, Chaoyang Dc, Beijing 100125, China
A002, 5F, Ai Tower, 701 Yunjin Road, Xuhui Dc, Shanghai 200232, China
800 Third Ave, 28F, New York, NY 10022, USA
Interviews with analysts
Products & prices
Customers & evaluation
Copyright ©2020 EqualOcean.com. All rights reserved.